

# Alain Matagne

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5039893/publications.pdf>

Version: 2024-02-01

16  
papers

2,883  
citations

623574

14  
h-index

940416

16  
g-index

16  
all docs

16  
docs citations

16  
times ranked

2242  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 372, 11-20.          | 1.3 | 27        |
| 2  | Anticonvulsant and antiepileptogenic effects of system xc <sup>-</sup> inactivation in chronic epilepsy models. <i>Epilepsia</i> , 2019, 60, 1412-1423.   | 2.6 | 20        |
| 3  | Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. <i>Epilepsia</i> , 2016, 57, 538-548.  | 2.6 | 137       |
| 4  | Status epilepticus induction has prolonged effects on the efficacy of antiepileptic drugs in the 6-Hz seizure model. <i>Epilepsy and Behavior</i> , 2015, 49, 55-60.  | 0.9 | 13        |
| 5  | Genetic background of mice strongly influences treatment resistance in the 6ÂHz seizure model. <i>Epilepsia</i> , 2015, 56, 310-318.  | 2.6 | 42        |
| 6  | Low potency and limited efficacy of antiepileptic drugs in the mouse 6Hz corneal kindling model. <i>Epilepsy Research</i> , 2014, 108, 675-683.   | 0.8 | 43        |
| 7  | 11-Deoxycortisol impedes GABAergic neurotransmission and induces drug-resistant status epilepticus in mice. <i>Neuropharmacology</i> , 2011, 60, 1098-1108.   | 2.0 | 10        |
| 8  | Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties. <i>European Journal of Pharmacology</i> , 2011, 664, 36-44.          | 1.7 | 198       |
| 9  | Profile of the new pyrrolidone derivative seletacetam (ucb 44212) in animal models of epilepsy. <i>European Journal of Pharmacology</i> , 2009, 614, 30-37.   | 1.7 | 24        |
| 10 | Benefit of combination therapy in epilepsy: A review of the preclinical evidence with levetiracetam. <i>Epilepsia</i> , 2009, 50, 387-397.  | 2.6 | 97        |
| 11 | Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. <i>Epilepsia</i> , 2009, 50, 1729-1740.  | 2.6 | 97        |
| 12 | SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. <i>Neuropharmacology</i> , 2008, 54, 715-720. | 2.0 | 151       |
| 13 | The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 9861-9866.                  | 3.3 | 1,431     |
| 14 | Use of epileptic animals for adverse effect testing. <i>Epilepsy Research</i> , 2002, 50, 55-65.  | 0.8 | 45        |
| 15 | Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. <i>European Journal of Pharmacology</i> , 1998, 353, 191-206.   | 1.7 | 432       |
| 16 | Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man. <i>Epilepsy Research</i> , 1998, 31, 59-71.  | 0.8 | 116       |